Show simple item record

dc.contributor.authorEAC
dc.date.accessioned2021-06-16T09:09:57Z
dc.date.available2021-06-16T09:09:57Z
dc.date.issued2018-04
dc.identifier.urihttp://hdl.handle.net/11671/24113
dc.descriptionPages 2, colored pictures. includes bibliographic references.en
dc.description.abstractLiver cancer is the leading cause of deaths in world. Chronic hepatitis B causes 80% of liver cancer causes in the EAC region. The combination of Aflatoxin exposure with hepatitis infection especially among people, who are malnourished or living with HIV results in a double disease burden that increases disease severity, reduces survivability and heightens liver cancer prevalence. The economic losses of residents of all EAC Partner States associated with morbidity and mortality from Aflatoxin-attributable liver cancer is of high magnitude.en
dc.description.sponsorshipThis policy brief was produced by the East African Community based on Technical Papers developed under the EAC Aflatoxin Prevention and Control Project funded by USAID East Africa Regional Economic Integration Office with technical backstopping from the International Institute of Tropical Agriculture (IITA).en
dc.language.isoenen
dc.publisherEACen
dc.relation.ispartofseriesEAC Policy Brief of Aflatoxin Prevention and Control;No. 4, 2018
dc.subjectAflatoxinen
dc.titleControlling the burden of liver disease through integration Hepatitis A and B vaccination into National Immunization programs of the EAC Partner States.en
dc.typePolicyen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record